Abbie S. Ireland

MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition

Gürkan Mollaoglu, Matthew R. Guthrie, Stefanie Böhm et al. · Cancer Cell · 2017 · 570 citations · Full text

Variant Neuroendocrine Subtype, Aurora Kinase Inhibition, Oncogenic Agent +9

MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate

Abbie S. Ireland, Alexi M. Micinski, David W. Kastner et al. · Cancer Cell · 2020 · 496 citations · Full text

Neuroendocrine Fate, Oncogenic Agent, Medicine +7

Inosine Monophosphate Dehydrogenase Dependence in a Subset of Small Cell Lung Cancers

Fang Huang, Min Ni, Milind D. Chalishazar et al. · Cell Metabolism · 2018 · 193 citations · Full text

Tumor Biology, Oncogenic Agent, Medicine +7

MYC-Driven Small-Cell Lung Cancer is Metabolically Distinct and Vulnerable to Arginine Depletion

Milind D. Chalishazar, Sarah J. Wait, Fang Huang et al. · Clinical Cancer Research · 2019 · 173 citations

Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies

Robert J. Cardnell, Lerong Li, Triparna Sen et al. · Oncotarget · 2017 · 91 citations · Full text